What ResMed's Quarter ended Sep 30, 2026 10-Q says: 4 signals
ResMed filed its latest 10-Q with the SEC on Oct 29, 2026. It discusses digital transformation, divestiture and international growth.
Public (RMD)Medical Equipment Manufacturing10,000+ employeesresmed.comLinkedIn
Get ResMed's live signals in Claude or ChatGPT, or by API
What changed at ResMed this week? Use Autobound signals for resmed.com.- Filed
- Oct 29, 2026
- Period
- Quarter ended Sep 30, 2026
- Filings
- 3
- Signals
- 23
Source: Autobound Signal API · 63 signals tracked for ResMed · updated
10-Q · latest 10
What ResMed's 10-Q filings say
- SEC EDGAR
10-Q · Quarter ended Sep 30, 2026
Filed · 4 signals
ResMed completed MatrixCare business sale on September 1, 2026, recognizing $62 million gain
ResMed divested its MatrixCare business on September 1, 2026, as part of a portfolio optimization strategy to focus on core growth areas.
$62M
gain recognized on divestment of MatrixCare business
ResMed spent $8 million on supply chain systems transformation and professional fees in Q1
During the three months ended September 30, 2026, ResMed incurred $8 million in restructuring and business transformation costs primarily related to supply chain processes and systems transformation initiatives.
$8M
professional fees related to supply chain processes and systems transformation initiatives
ResMed Incurs $28M in Restructuring and Transformation Costs in Q1 Fiscal 2027
ResMed recorded $20 million in restructuring and business transformation costs within SG&A and $8 million within cost of sales, primarily driven by professional fees for supply chain transformation and growth initiatives.
$20M
restructuring and business transformation costs in SG&A
Rest of World Sleep and Breathing Health revenue rose 8% to $426 million
Rest of World revenue increased to $426 million from $394.7 million in the prior-year period, driven by unit demand and device fleet renewals in France.
$426M
Rest of World Sleep and Breathing Health net revenue
8%
increase in Rest of World Sleep and Breathing Health net revenue
- SEC EDGAR
10-Q
Filed · 7 signals
ResMed commits to $984M in purchase obligations for the upcoming year
The company has disclosed nearly $1 billion in contractual purchase obligations due within the next 12 months, signaling a massive, planned spend on its supply chain and manufacturing operations.
$984M
Purchase obligations due by March 31, 2027
ResMed using $3.4B currency swap program to manage risk from international manufacturing.
With manufacturing concentrated in Australia and Singapore, ResMed faces significant financial risk from currency fluctuations.
$3.4B
Notional value of outstanding foreign cross-currency swaps
MUFG Union BankWestpac Banking Corporation
ResMed warns that inflation may adversely affect gross margin and operating results.
The company explicitly states that rising costs for products, freight, and overhead may negatively impact its ability to maintain current margin levels, creating a need for cost-reduction and efficiency solutions.
ResMed flags potential inability to pass on rising costs through price increases.
The company's statement on inflation indicates a potential lack of pricing power, which could compress margins.
ResMed cites inflation impacting product costs, freight, and overhead.
The company is facing rising costs for its products, shipping, and general overhead due to inflation, which could negatively impact operating results and gross margins.
- SEC EDGAR
10-Q
Filed · 12 signals
Company has $861M in purchase obligations, with $840M due in 2026
ResMed has committed to $861.2 million in purchase obligations, with the vast majority ($839.5 million) due within the next year.
$861.2M
Total purchase obligations
Showing 10 of 23 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
ResMed earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Actively deploying ML, AI, and Generative AI in digital health products.ResMed is rolling out AI-powered features like 'Dawn' (a generative AI assistant) and 'Comfort Match' (an AI-enabled settings tool) to enhance patient support and adherence. This indicates active budget and resource allocation for AI development, data infrastructure, and cloud services. | |
| Experiencing massive growth in API calls, focusing on interoperability.The company's digital health ecosystem handled over 3 billion API calls in the quarter, a 40% year-over-year increase, highlighting a focus on data interoperability. This massive data volume signals needs for robust cloud infrastructure, data management, analytics, and API security solutions. | |
| Launching multiyear programs for planning systems and automationTo drive operating leverage, ResMed is implementing multiyear productivity programs focused on improved planning systems and large-scale automation. This signals budget and active evaluation for enterprise resource planning (ERP), supply chain planning software, and factory automation technologies. | |
| Restructuring software portfolio to focus on high-growth SaaSResMed is actively reallocating investment within its Residential Care Software (RCS) division, focusing on high-growth SaaS platforms (MEDIFOX, Brightree, MatrixCare) while reducing exposure to low-margin services. This portfolio management initiative creates opportunities for vendors who can support the scaling of their core SaaS products. | |
| Delivered strong 9% revenue growth and returned $238M to shareholders.The company reported strong financial performance with 9% revenue growth and significant capital return to shareholders. This financial health and strong free cash flow demonstrates the capacity to fund strategic initiatives and new investments. | |
| Investing to accelerate growth in direct-to-consumer (DTC) Asian markets.The company is focused on accelerating growth in DTC markets including China, India, and Korea. This geographic expansion creates opportunities for vendors in international marketing, e-commerce platforms, and localized digital engagement. |
Signal API · MCP
Track ResMed with the Signal API
One POST /v1/companies/enrich call with resmed.com returns ResMed 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"resmed.com","signal_types":["sec-10q"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.
Same industry
10-Q at related companies
Questions about ResMed 10-Q
When did ResMed file its latest 10-Q?
What did ResMed disclose in its latest 10-Q?
What did ResMed say on its recent earnings calls?
Where can I read ResMed's 10-Q filing?
Page updated , the date of the newest row on this page.
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .